Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib in Neoadjuvant/Adjuvant EGFR-mutant NSCLC
NCT03349203Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in epidermal growth factor receptor positive non-small cell lung cancer, sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
epidermal growth factor receptor positive non-small cell lung cancer
Beyond the preview
Go deeper on NCT03349203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349203.